Wolverine Stack
Also known as · BPC-157 + TB-500 · Recovery stack
- EvidencePreclinical
- CategoryTissue support & recovery
- RoutesubQ / IM
- Half-lifeSee individual components
- Form
- Co-lyophilized powder
- BPC-157
- 10 mg
- TB-500
- 10 mg
- Total peptide
- 20 mg total
- Purity
- ≥98% (HPLC, per component)
- COA
- Available on request
In stock
Request pricing
Contact us for current pricing and bulk quotes.
Reserve vial →For research use only. Not for human consumption. Buyers must be affiliated with a research institution.
01 / Research summary
What the literature reports
The Wolverine Stack combines BPC-157 (10 mg) and TB-500 (10 mg) in a single lyophilized vial. Both peptides are researched individually for tendon, ligament, and soft-tissue recovery in preclinical models.
Cellaire classifies the Wolverine Stack as preclinical evidence. There is no published clinical trial of the specific BPC-157 + TB-500 combination. Each component's individual evidence is on its own product page.
02 / Reconstitution
Reconstitution reference
Illustrative unit math for a 20 mg vial reconstituted with 2 mL bacteriostatic water. This is not a dose recommendation.
03 / Overview
Molecular overview
The Wolverine Stack is a co-lyophilized vial containing 10 mg BPC-157 and 10 mg TB-500 (20 mg total peptide). It is not a covalent conjugate — each peptide remains a separate molecule.
BPC-157 contributes the pentadecapeptide gastric-juice fragment (angiogenic / VEGFR2 pathway). TB-500 contributes the thymosin β4 fragment 17–23 (actin-binding / cell migration).
The combination is unstudied as a single product. Each peptide's individual preclinical literature is cited on its dedicated product page.
Neither component is FDA-approved. Both appear on the FDA Category 2 bulk substances review list.
04 / References